T1	Participants 282 357	Thirty-two patients undergoing six courses of paclitaxel-based chemotherapy
T2	Participants 1136 1155	patients in Group I
T3	Participants 1188 1205	those in Group II
T4	Participants 1365 1385	patients with cancer
